BCMA-targeted therapies for multiple myeloma: latest updates from 2024 ASH annual meeting

Huijian Zheng; Huajian Xian; Wenjie Zhang; Chaoqun Lu; Renyao Pan; Han Liu; Zhenshu Xu

doi:10.1186/s13045-025-01675-5

Journal of Hematology & Oncology (Mar 2025)

BCMA-targeted therapies for multiple myeloma: latest updates from 2024 ASH annual meeting

Huijian Zheng,
Huajian Xian,
Wenjie Zhang,
Chaoqun Lu,
Renyao Pan,
Han Liu,
Zhenshu Xu

Affiliations

Huijian Zheng: Fujian Provincial Key Laboratory on Hematology, Fujian Institute of Hematology, Fujian Medical University Union Hospital
Huajian Xian: Shanghai Institute of Hematology, State Key Laboratory of Medical Genomics, Ruijin Hospital, National Research Center for Translational Medicine at Shanghai, Shanghai Jiao Tong University School of Medicine
Wenjie Zhang: Fujian Provincial Key Laboratory on Hematology, Fujian Institute of Hematology, Fujian Medical University Union Hospital
Chaoqun Lu: Shanghai Institute of Hematology, State Key Laboratory of Medical Genomics, Ruijin Hospital, National Research Center for Translational Medicine at Shanghai, Shanghai Jiao Tong University School of Medicine
Renyao Pan: Fujian Provincial Key Laboratory on Hematology, Fujian Institute of Hematology, Fujian Medical University Union Hospital
Han Liu: Shanghai Institute of Hematology, State Key Laboratory of Medical Genomics, Ruijin Hospital, National Research Center for Translational Medicine at Shanghai, Shanghai Jiao Tong University School of Medicine
Zhenshu Xu: Fujian Provincial Key Laboratory on Hematology, Fujian Institute of Hematology, Fujian Medical University Union Hospital

DOI: https://doi.org/10.1186/s13045-025-01675-5
Journal volume & issue: Vol. 18, no. 1
pp. 1 – 4

Abstract

Read online

Abstract B-cell maturation antigen (BCMA) is currently the most extensively explored target for multiple myeloma (MM). BCMA-targeted therapies such as antibody-drug conjugate (ADC), bispecific antibodies (BsAbs), chimeric antigen receptor T(CAR-T) cell have shown promising therapeutic prospects in MM. We have summarized the latest reports on the three types of drugs for MM at the 2024 ASH Annual Meeting.

Published in Journal of Hematology & Oncology

ISSN: 1756-8722 (Online)
Publisher: BMC
Country of publisher: United Kingdom
LCC subjects: Medicine: Internal medicine: Specialties of internal medicine: Diseases of the blood and blood-forming organs; Medicine: Internal medicine: Neoplasms. Tumors. Oncology. Including cancer and carcinogens
Website: https://jhoonline.biomedcentral.com/

About the journal

Abstract

Keywords